Annual CFO
-$8.99 M
+$1.23 M+12.05%
December 31, 2022
Summary
- As of February 8, 2025, NAVB annual cash flow from operations is -$8.99 million, with the most recent change of +$1.23 million (+12.05%) on December 31, 2022.
- During the last 3 years, NAVB annual CFO has risen by +$368.10 thousand (+3.93%).
- NAVB annual CFO is now -115.21% below its all-time high of $59.08 million, reached on December 31, 2017.
Performance
NAVB Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$10.25 M
-$14.94 M-318.51%
September 30, 2023
Summary
- As of February 8, 2025, NAVB quarterly cash flow from operations is -$10.25 million, with the most recent change of -$14.94 million (-318.51%) on September 30, 2023.
- Over the past year, NAVB quarterly CFO has dropped by -$14.94 million (-318.51%).
- NAVB quarterly CFO is now -115.15% below its all-time high of $67.66 million, reached on March 31, 2017.
Performance
NAVB Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$9.71 M
-$8.39 M-634.38%
September 30, 2023
Summary
- As of February 8, 2025, NAVB TTM cash flow from operations is -$9.71 million, with the most recent change of -$8.39 million (-634.38%) on September 30, 2023.
- Over the past year, NAVB TTM CFO has dropped by -$8.39 million (-634.38%).
- NAVB TTM CFO is now -113.33% below its all-time high of $72.90 million, reached on March 31, 2017.
Performance
NAVB TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
NAVB Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +12.1% | -318.5% | -634.4% |
| 3 y3 years | +3.9% | -318.5% | -634.4% |
| 5 y5 years | -115.2% | -318.5% | -634.4% |
NAVB Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +12.1% | -318.5% | at low | -634.4% | +4.9% |
| 5 y | 5-year | -9.9% | +12.1% | -318.5% | at low | -634.4% | +8.9% |
| alltime | all time | -115.2% | +74.8% | -115.2% | +8.1% | -113.3% | +74.7% |
Navidea Biopharmaceuticals Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2023 | - | -$10.25 M(-318.5%) | -$9.71 M(+634.4%) |
| Jun 2023 | - | $4.69 M(-372.4%) | -$1.32 M(-83.8%) |
| Mar 2023 | - | -$1.72 M(-29.2%) | -$8.15 M(-9.3%) |
| Dec 2022 | -$8.99 M(-12.1%) | -$2.43 M(+31.0%) | -$8.99 M(-3.2%) |
| Sep 2022 | - | -$1.86 M(-13.1%) | -$9.28 M(-1.6%) |
| Jun 2022 | - | -$2.14 M(-16.3%) | -$9.44 M(-2.8%) |
| Mar 2022 | - | -$2.56 M(-6.3%) | -$9.71 M(-5.0%) |
| Dec 2021 | -$10.22 M(+25.0%) | -$2.73 M(+35.6%) | -$10.22 M(+1.7%) |
| Sep 2021 | - | -$2.01 M(-16.7%) | -$10.05 M(-5.8%) |
| Jun 2021 | - | -$2.41 M(-21.1%) | -$10.67 M(+3.7%) |
| Mar 2021 | - | -$3.06 M(+19.8%) | -$10.29 M(+25.8%) |
| Dec 2020 | -$8.17 M(-12.6%) | -$2.56 M(-2.8%) | -$8.17 M(-2.1%) |
| Sep 2020 | - | -$2.63 M(+29.3%) | -$8.35 M(+3.6%) |
| Jun 2020 | - | -$2.03 M(+113.9%) | -$8.06 M(-1.0%) |
| Mar 2020 | - | -$951.30 K(-65.2%) | -$8.14 M(-13.0%) |
| Dec 2019 | -$9.35 M(-318.8%) | -$2.73 M(+16.7%) | -$9.35 M(+6.9%) |
| Sep 2019 | - | -$2.34 M(+10.9%) | -$8.75 M(+5.5%) |
| Jun 2019 | - | -$2.11 M(-2.4%) | -$8.29 M(-289.8%) |
| Mar 2019 | - | -$2.17 M(+1.8%) | $4.37 M(+2.2%) |
| Dec 2018 | $4.28 M(-92.8%) | -$2.13 M(+12.7%) | $4.28 M(-3.7%) |
| Sep 2018 | - | -$1.89 M(-117.9%) | $4.44 M(-17.5%) |
| Jun 2018 | - | $10.55 M(-566.8%) | $5.38 M(-149.7%) |
| Mar 2018 | - | -$2.26 M(+15.2%) | -$10.84 M(-118.3%) |
| Dec 2017 | $59.08 M(+1561.1%) | -$1.96 M(+107.3%) | $59.08 M(-6.7%) |
| Sep 2017 | - | -$946.50 K(-83.3%) | $63.30 M(-5.4%) |
| Jun 2017 | - | -$5.67 M(-108.4%) | $66.91 M(-8.2%) |
| Mar 2017 | - | $67.66 M(+2896.8%) | $72.90 M(+1949.5%) |
| Dec 2016 | $3.56 M(-118.6%) | $2.26 M(-15.0%) | $3.56 M(-222.8%) |
| Sep 2016 | - | $2.66 M(+722.5%) | -$2.90 M(-70.0%) |
| Jun 2016 | - | $322.90 K(-119.2%) | -$9.64 M(-42.1%) |
| Mar 2016 | - | -$1.68 M(-60.0%) | -$16.65 M(-12.7%) |
| Dec 2015 | -$19.08 M(-34.5%) | -$4.19 M(+2.6%) | -$19.08 M(-3.2%) |
| Sep 2015 | - | -$4.09 M(-38.8%) | -$19.71 M(-11.7%) |
| Jun 2015 | - | -$6.68 M(+62.6%) | -$22.33 M(-7.2%) |
| Mar 2015 | - | -$4.11 M(-14.9%) | -$24.06 M(-17.4%) |
| Dec 2014 | -$29.13 M(-18.2%) | -$4.83 M(-28.1%) | -$29.13 M(-17.9%) |
| Sep 2014 | - | -$6.71 M(-20.3%) | -$35.46 M(-7.8%) |
| Jun 2014 | - | -$8.42 M(-8.2%) | -$38.45 M(+2.8%) |
| Mar 2014 | - | -$9.17 M(-17.8%) | -$37.39 M(+5.0%) |
| Dec 2013 | -$35.61 M(+48.9%) | -$11.16 M(+14.9%) | -$35.61 M(+12.1%) |
| Sep 2013 | - | -$9.71 M(+31.9%) | -$31.78 M(+17.1%) |
| Jun 2013 | - | -$7.36 M(-0.5%) | -$27.13 M(+9.7%) |
| Mar 2013 | - | -$7.40 M(+1.1%) | -$24.73 M(+3.4%) |
| Dec 2012 | -$23.92 M(+49.4%) | -$7.32 M(+44.5%) | -$23.92 M(-9.1%) |
| Sep 2012 | - | -$5.06 M(+2.3%) | -$26.32 M(+5.4%) |
| Jun 2012 | - | -$4.95 M(-24.9%) | -$24.97 M(+20.0%) |
| Mar 2012 | - | -$6.59 M(-32.2%) | -$20.81 M(+30.0%) |
| Dec 2011 | -$16.01 M(+209.7%) | -$9.71 M(+161.9%) | -$16.01 M(+102.9%) |
| Sep 2011 | - | -$3.71 M(+366.4%) | -$7.89 M(+47.9%) |
| Jun 2011 | - | -$795.50 K(-55.5%) | -$5.34 M(-16.4%) |
| Mar 2011 | - | -$1.79 M(+12.1%) | -$6.38 M(+23.5%) |
| Dec 2010 | -$5.17 M(+248.8%) | -$1.60 M(+38.3%) | -$5.17 M(+35.4%) |
| Sep 2010 | - | -$1.15 M(-37.4%) | -$3.82 M(+22.4%) |
| Jun 2010 | - | -$1.84 M(+220.1%) | -$3.12 M(+90.0%) |
| Mar 2010 | - | -$575.90 K(+134.8%) | -$1.64 M(+10.8%) |
| Dec 2009 | -$1.48 M(-51.0%) | -$245.30 K(-46.1%) | -$1.48 M(-41.6%) |
| Sep 2009 | - | -$455.50 K(+24.7%) | -$2.54 M(-20.5%) |
| Jun 2009 | - | -$365.20 K(-12.2%) | -$3.19 M(-6.1%) |
| Mar 2009 | - | -$416.10 K(-68.0%) | -$3.40 M(+12.4%) |
| Dec 2008 | -$3.02 M | -$1.30 M(+17.1%) | -$3.02 M(+71.7%) |
| Sep 2008 | - | -$1.11 M(+94.3%) | -$1.76 M(+87.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2008 | - | -$571.00 K(+1246.7%) | -$941.10 K(-25.9%) |
| Mar 2008 | - | -$42.40 K(+14.6%) | -$1.27 M(+0.4%) |
| Dec 2007 | -$1.27 M(-64.4%) | -$37.00 K(-87.3%) | -$1.27 M(-44.8%) |
| Sep 2007 | - | -$290.70 K(-67.7%) | -$2.29 M(-21.9%) |
| Jun 2007 | - | -$899.80 K(+2280.4%) | -$2.93 M(-0.0%) |
| Mar 2007 | - | -$37.80 K(-96.4%) | -$2.94 M(-17.5%) |
| Dec 2006 | -$3.56 M(+18.5%) | -$1.06 M(+14.1%) | -$3.56 M(+19.4%) |
| Sep 2006 | - | -$932.70 K(+3.5%) | -$2.98 M(-19.4%) |
| Jun 2006 | - | -$901.00 K(+36.6%) | -$3.70 M(+32.1%) |
| Mar 2006 | - | -$659.40 K(+35.7%) | -$2.80 M(-6.8%) |
| Dec 2005 | -$3.00 M(+263.7%) | -$485.90 K(-70.6%) | -$3.00 M(+10.5%) |
| Sep 2005 | - | -$1.65 M(>+9900.0%) | -$2.72 M(+83.8%) |
| Jun 2005 | - | -$2800.00(-99.7%) | -$1.48 M(-14.2%) |
| Mar 2005 | - | -$862.50 K(+329.5%) | -$1.72 M(+108.7%) |
| Dec 2004 | -$825.40 K(-54.5%) | -$200.80 K(-51.3%) | -$825.50 K(-45.7%) |
| Sep 2004 | - | -$412.10 K(+66.4%) | -$1.52 M(+5.7%) |
| Jun 2004 | - | -$247.60 K(-807.4%) | -$1.44 M(-6.2%) |
| Mar 2004 | - | $35.00 K(-103.9%) | -$1.53 M(-15.5%) |
| Dec 2003 | -$1.81 M(-39.8%) | -$895.10 K(+170.8%) | -$1.81 M(+29.8%) |
| Sep 2003 | - | -$330.60 K(-3.6%) | -$1.40 M(-27.9%) |
| Jun 2003 | - | -$342.80 K(+39.3%) | -$1.94 M(-30.8%) |
| Mar 2003 | - | -$246.00 K(-48.6%) | -$2.80 M(-7.1%) |
| Dec 2002 | -$3.02 M(+988.9%) | -$478.80 K(-45.1%) | -$3.02 M(-6.1%) |
| Sep 2002 | - | -$872.30 K(-27.6%) | -$3.21 M(+68.2%) |
| Jun 2002 | - | -$1.21 M(+162.1%) | -$1.91 M(-2499.1%) |
| Mar 2002 | - | -$459.90 K(-31.8%) | $79.60 K(-128.7%) |
| Dec 2001 | -$277.00 K(-116.6%) | -$674.60 K(-256.9%) | -$276.90 K(-115.1%) |
| Sep 2001 | - | $430.00 K(-45.2%) | $1.84 M(-18.8%) |
| Jun 2001 | - | $784.10 K(-196.0%) | $2.26 M(+44.4%) |
| Mar 2001 | - | -$816.40 K(-156.8%) | $1.57 M(-6.2%) |
| Dec 2000 | $1.67 M(-15.3%) | $1.44 M(+68.1%) | $1.67 M(+619.2%) |
| Sep 2000 | - | $855.70 K(+860.4%) | $232.30 K(-137.3%) |
| Jun 2000 | - | $89.10 K(-112.5%) | -$623.40 K(-61.3%) |
| Mar 2000 | - | -$712.50 K(-20.8%) | -$1.61 M(-86.1%) |
| Dec 1999 | $1.97 M(-108.6%) | - | - |
| Jun 1999 | - | -$900.00 K(-59.1%) | -$11.56 M(-33.8%) |
| Mar 1999 | - | -$2.20 M(-49.6%) | -$17.46 M(-24.3%) |
| Dec 1998 | -$23.06 M(+6.3%) | -$4.36 M(+6.5%) | -$23.06 M(-3.5%) |
| Sep 1998 | - | -$4.10 M(-39.7%) | -$23.90 M(-2.4%) |
| Jun 1998 | - | -$6.80 M(-12.8%) | -$24.50 M(+10.4%) |
| Mar 1998 | - | -$7.80 M(+49.9%) | -$22.20 M(+2.3%) |
| Dec 1997 | -$21.70 M(+49.7%) | -$5.20 M(+10.7%) | -$21.70 M(+0.0%) |
| Sep 1997 | - | -$4.70 M(+4.4%) | -$21.70 M(+13.6%) |
| Jun 1997 | - | -$4.50 M(-38.4%) | -$19.10 M(+6.7%) |
| Mar 1997 | - | -$7.30 M(+40.4%) | -$17.90 M(+23.4%) |
| Dec 1996 | -$14.50 M(+57.6%) | -$5.20 M(+147.6%) | -$14.50 M(+21.8%) |
| Sep 1996 | - | -$2.10 M(-36.4%) | -$11.90 M(-1.7%) |
| Jun 1996 | - | -$3.30 M(-15.4%) | -$12.10 M(+11.0%) |
| Mar 1996 | - | -$3.90 M(+50.0%) | -$10.90 M(+18.5%) |
| Dec 1995 | -$9.20 M(0.0%) | -$2.60 M(+13.0%) | -$9.20 M(+8.2%) |
| Sep 1995 | - | -$2.30 M(+9.5%) | -$8.50 M(+9.0%) |
| Jun 1995 | - | -$2.10 M(-4.5%) | -$7.80 M(-11.4%) |
| Mar 1995 | - | -$2.20 M(+15.8%) | -$8.80 M(-4.3%) |
| Dec 1994 | -$9.20 M(+24.3%) | -$1.90 M(+18.8%) | -$9.20 M(-7.1%) |
| Sep 1994 | - | -$1.60 M(-48.4%) | -$9.90 M(0.0%) |
| Jun 1994 | - | -$3.10 M(+19.2%) | -$9.90 M(+16.5%) |
| Mar 1994 | - | -$2.60 M(0.0%) | -$8.50 M(+14.9%) |
| Dec 1993 | -$7.40 M(+208.3%) | -$2.60 M(+62.5%) | -$7.40 M(+54.2%) |
| Sep 1993 | - | -$1.60 M(-5.9%) | -$4.80 M(+50.0%) |
| Jun 1993 | - | -$1.70 M(+13.3%) | -$3.20 M(+113.3%) |
| Mar 1993 | - | -$1.50 M | -$1.50 M |
| Dec 1992 | -$2.40 M | - | - |
FAQ
- What is Navidea Biopharmaceuticals annual cash flow from operations?
- What is the all time high annual CFO for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals annual CFO year-on-year change?
- What is Navidea Biopharmaceuticals quarterly cash flow from operations?
- What is the all time high quarterly CFO for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals quarterly CFO year-on-year change?
- What is Navidea Biopharmaceuticals TTM cash flow from operations?
- What is the all time high TTM CFO for Navidea Biopharmaceuticals?
- What is Navidea Biopharmaceuticals TTM CFO year-on-year change?
What is Navidea Biopharmaceuticals annual cash flow from operations?
The current annual CFO of NAVB is -$8.99 M
What is the all time high annual CFO for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high annual cash flow from operations is $59.08 M
What is Navidea Biopharmaceuticals annual CFO year-on-year change?
Over the past year, NAVB annual cash flow from operations has changed by +$1.23 M (+12.05%)
What is Navidea Biopharmaceuticals quarterly cash flow from operations?
The current quarterly CFO of NAVB is -$10.25 M
What is the all time high quarterly CFO for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high quarterly cash flow from operations is $67.66 M
What is Navidea Biopharmaceuticals quarterly CFO year-on-year change?
Over the past year, NAVB quarterly cash flow from operations has changed by -$14.94 M (-318.51%)
What is Navidea Biopharmaceuticals TTM cash flow from operations?
The current TTM CFO of NAVB is -$9.71 M
What is the all time high TTM CFO for Navidea Biopharmaceuticals?
Navidea Biopharmaceuticals all-time high TTM cash flow from operations is $72.90 M
What is Navidea Biopharmaceuticals TTM CFO year-on-year change?
Over the past year, NAVB TTM cash flow from operations has changed by -$8.39 M (-634.38%)